Alector Enters Global License Agreement with Genentech for Brain Penetrant GCase Enzyme Replacement Therapy for Parkinson’s Disease and Other Neurodegenerative Diseases

Arnon Rosenthal, Chief Executive Officer of Alector

“Deficient GCase activity is increasingly recognized as a contributor to Parkinson’s Disease, and there is still no approved therapy that addresses the underlying enzyme deficiency.”

Arnon Rosenthal, Chief Executive Officer of Alector

“The challenge in treating GCase deficiency is twofold: engineering an enzyme with optimal activity and durability and successfully delivering it to the brain.”

Arnon Rosenthal, Chief Executive Officer of Alector

“AL050 addresses this by pairing an engineered GCase enzyme with our proprietary Alector Brain Carrier technology designed to cross the blood-brain barrier.”

Arnon Rosenthal, Chief Executive Officer of Alector

“Genentech’s long-standing commitment to Parkinson’s Disease makes them an ideal partner as this program moves toward the clinic”

Boris L. Zaïtra, Head of Roche Corporate Business Development

“Parkinson’s Disease is one of the fastest-growing neurological conditions worldwide”

Boris L. Zaïtra, Head of Roche Corporate Business Development

“By partnering with companies such as Alector we aim to delay or halt the progression of Parkinson’s so patients maintain and prolong their independence.”

Arnon Rosenthal, Chief Executive Officer of Alector

“This partnership extends our cash runway into 2029, providing resources to advance our fully active, subcutaneously delivered, brain-enabled anti-Aβ antibody to multi-cohort clinical data in Alzheimer’s patients, and move our subcutaneously delivered, brain-enabled Tau siRNA and alpha- synuclein siRNA programs through IND-enabling studies and to IND filings”